The Biosimilars Forum Announces Meaghan Rose Smith as Executive Director
Smith is Obama-Biden HHS and Senate Veteran Who Will Lead Organization’s Mission to Increase Patient Access to Lower-Cost Biosimilars
Washington, DC — Today, the Biosimilars Forum announced that its Board has chosen Meaghan Rose Smith as the non-profit’s first Executive Director to spearhead the organization’s work to advance lower-cost biosimilars development and increase patient availability to lower-cost biosimilar treatments. The members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.
The Biosimilars Forum is thrilled to have Meaghan on board as our Executive Director,” said Juliana Reed, President of the Biosimilars Forum. “This is a critical time for the industry and her extensive health care policy experience in both the private and public sector will be invaluable as we work to realize the significant cost-savings potential of biosimilars and face potential challenges to the BPCIA.
Biosimilars are key to lowering health care costs and can save the U.S. billions of dollars” said Meaghan Rose Smith, Executive Director of the Biosimilars Forum. “Now more than ever, as we’re dealing with the devastating impact of the coronavirus pandemic and the Supreme Court considers the BPCIA with the ACA, the future of biosimilars is critical for patients and our country.
Smith has held several leadership positions in government. She served as a Senior Advisor and Director of Communications at the U.S. Department of Health and Human Services (HHS) during the Obama Administration working on implementation of the Affordable Care Act (ACA). Prior to that she worked for U.S. Senator Brian Schatz, the U.S. Senate Finance Committee during the passage of the ACA as well as in multiple House offices. Most recently she led the health care practice at the public affairs firm SKDKnickerbocker creating strategies and advising multi-party coalitions, CEOs and government leaders.